Clinical trial · Interventional
Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer
Randomized Controlled Study of Iron Supplementation to Support the Response to Recombinant Human Erythropoietin for the Treatment of Chemotherapy-Induced Anaemia
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Epoetin alfa and epoetin beta may cause the body to make more red blood cells. Red blood cells contain iron that is needed to carry oxygen to the tissues. It is not yet known whether epoetin alfa or epoetin beta are more effective when given with or without iron infusion in treating anemia in patients with cancer. PURPOSE: This randomized phase III trial is studying epoetin alfa or epoetin beta to compare how well they work with or without iron infusion in treating anemia in patients with cancer.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anemia | — | UNRESOLVED | — |
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Multiple Myeloma and Plasma Cell Neoplasm | — | UNRESOLVED | — |
| Unspecified Adult Solid Tumor, Protocol Specific | Adult Solid Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| epoetin alfa | Biological | — | UNRESOLVED |
| epoetin beta | Biological | — | UNRESOLVED |
| iron dextran complex | Dietary Supplement | — | UNRESOLVED |
| iron sucrose injection | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Maximum hemoglobin achieved
Secondary outcomes (1)
- measure
- Time to zenith hemoglobin or achievement of hemoglobin level ≥ 13 g/dL
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of nonmyeloid malignancy * No primary bone marrow malignancies except multiple myeloma, chronic lymphocytic leukemia, or indolent non-Hodgkin lymphoma * Candidate for erythropoietin stimulatory activity therapy for anemia due to cancer and/or chemotherapy * Baseline hemoglobin ≤ 10.5 g/dL * Planning to receive ≥ 6 additional weeks of chemotherapy for the malignancy * Demonstrates iron-replete status as defined by all of the following parameters: * Percent saturation of transferrin ≥ 20% * Serum ferritin 225-2,250 pmol/L * Reticulocyte hemoglobin content \> 31 pg * Zinc protoporphyrin \< 80 µg/dL * No anemia of origin other than cancer or cancer chemotherapy PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * No allergy or intolerance to recombinant epoetin alfa or epoetin beta * No known sensitivity to iron sucrose injection or iron dextran complex * No uncontrolled hypertension * No active infection * No active bleeding PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior iron sucrose injection or iron dextran complex therapy * More than 6 months since prior and no concurrent transfusion
References
Publications (0)
Data not yet available